Cargando…
Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study
AIM: The aim of this study is to evaluate long-term efficacy of intravitreal injections of aflibercept as primary treatment for subfoveal/juxtafoveal myopic choroidal neovascularisation (CNV). METHODS: Thirty-eight treatment-naive eyes of thirty-eight patients with subfoveal/juxtafoveal myopic CNV r...
Autores principales: | Bruè, C, Pazzaglia, A, Mariotti, C, Reibaldi, M, Giovannini, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709541/ https://www.ncbi.nlm.nih.gov/pubmed/26514244 http://dx.doi.org/10.1038/eye.2015.199 |
Ejemplares similares
-
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
por: Nawar, Amin E., et al.
Publicado: (2020) -
Effect of Intravitreal Ranibizumab in the Treatment of Peripapillary Choroidal Neovascularisation
por: Hamoudi, Hassan, et al.
Publicado: (2011) -
Myopic choroidal neovascularisation: current concepts and update on clinical management
por: Wong, Tien Y, et al.
Publicado: (2015) -
Recurrence risk of myopic choroidal neovascularisation: a systematic review of current study
por: Victor, Andi Arus, et al.
Publicado: (2023) -
A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation
por: Loutfi, M., et al.
Publicado: (2015)